docetaxel anhydrous has been researched along with neuropeptide y in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (neuropeptide y) | Trials (neuropeptide y) | Recent Studies (post-2010) (neuropeptide y) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 10,663 | 152 | 2,269 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | neuropeptide y (IC50) |
|---|---|---|---|
| Neuropeptide Y receptor type 1 | Homo sapiens (human) | 0.0014 | |
| Neuropeptide Y receptor type 2 | Homo sapiens (human) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lundholm, M; Nilsson, RJA; Schröder, M; Thellenberg-Karlsson, C; Tjon-Kon-Fat, LA; Widmark, A; Wikström, P; Wurdinger, T | 1 |
1 trial(s) available for docetaxel anhydrous and neuropeptide y
| Article | Year |
|---|---|
Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
Topics: Aged; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Blood Platelets; Disease-Free Survival; Docetaxel; Glutamate Carboxypeptidase II; Humans; Kallikreins; Male; Middle Aged; Neuropeptide Y; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2018 |